These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37030532)

  • 1. High- versus low-dose losartan and uric acid: An analysis from HEAAL.
    Ferreira JP; Zannad F; Kiernan MS; Konstam MA
    J Cardiol; 2023 Jul; 82(1):57-61. PubMed ID: 37030532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
    Ferreira JP; Konstam M; Rossignol P; Kiernan MS; Zannad F
    J Card Fail; 2023 Jan; 29(1):45-52. PubMed ID: 36244652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.
    Rossignol P; Dobre D; Gregory D; Massaro J; Kiernan M; Konstam MA; Zannad F
    Int J Cardiol; 2014 May; 173(3):380-7. PubMed ID: 24726210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
    Konstam MA; Neaton JD; Dickstein K; Drexler H; Komajda M; Martinez FA; Riegger GA; Malbecq W; Smith RD; Guptha S; Poole-Wilson PA;
    Lancet; 2009 Nov; 374(9704):1840-8. PubMed ID: 19922995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Doehner W; Anker SD; Butler J; Zannad F; Filippatos G; Ferreira JP; Salsali A; Kaempfer C; Brueckmann M; Pocock SJ; Januzzi JL; Packer M
    Eur Heart J; 2022 Sep; 43(36):3435-3446. PubMed ID: 35788657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
    Kiernan MS; Gregory D; Sarnak MJ; Rossignol P; Massaro J; Kociol R; Zannad F; Konstam MA
    JACC Heart Fail; 2015 Mar; 3(3):214-23. PubMed ID: 25742759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study.
    Ueno S; Hamada T; Taniguchi S; Ohtani N; Miyazaki S; Mizuta E; Ohtahara A; Ogino K; Yoshida A; Kuwabara M; Yoshida K; Ninomiya H; Kotake H; Taufiq F; Yamamoto K; Hisatome I
    Drug Res (Stuttg); 2016 Dec; 66(12):628-632. PubMed ID: 27643410
    [No Abstract]   [Full Text] [Related]  

  • 9. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
    Ferreira JP; Konstam MA; McMurray JJV; Butler J; Girerd N; Rossignol P; Sharma A; Voors AA; Lam CSP; Packer M; Zannad F
    Eur J Heart Fail; 2021 Sep; 23(9):1477-1484. PubMed ID: 34050594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
    Ohshiro K; Sakima A; Nakada S; Kohagura K; Yamazato M; Tana T; Ohya Y
    Clin Exp Hypertens; 2011; 33(8):565-70. PubMed ID: 21958001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
    Miao Y; Ottenbros SA; Laverman GD; Brenner BM; Cooper ME; Parving HH; Grobbee DE; Shahinfar S; de Zeeuw D; Lambers Heerspink HJ
    Hypertension; 2011 Jul; 58(1):2-7. PubMed ID: 21632472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX.
    Carnicelli AP; Sun JL; Alhanti B; Bjursell M; Perl S; Lytle B; Roe MT; Mentz RJ
    Am J Med; 2020 Dec; 133(12):e716-e721. PubMed ID: 32416181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
    Mogensen UM; Køber L; Jhund PS; Desai AS; Senni M; Kristensen SL; Dukát A; Chen CH; Ramires F; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Solomon SD; Swedberg K; Packer M; McMurray JJV;
    Eur J Heart Fail; 2018 Mar; 20(3):514-522. PubMed ID: 29193563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.
    Hu DY; Huang J; Cai NS; Zhu WL; Li YS; Massaad R; Hanson ME; Dickstein K
    Chin Med J (Engl); 2012 Nov; 125(21):3868-74. PubMed ID: 23106890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
    Carnicelli AP; Clare R; Chiswell K; Lytle B; Bjursell M; Perl S; Andersson K; Hedman K; Pagidipati N; Vemulapalli S; Roe MT; Mentz RJ
    Am J Cardiol; 2020 Jul; 127():64-72. PubMed ID: 32386813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular drugs and serum uric acid.
    Reyes AJ
    Cardiovasc Drugs Ther; 2003; 17(5-6):397-414. PubMed ID: 15107595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study.
    Rossignol P; Girerd N; Gregory D; Massaro J; Konstam MA; Zannad F
    Int J Cardiol; 2015; 187():183-9. PubMed ID: 25828348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
    Dang A; Zhang Y; Liu G; Chen G; Song W; Wang B
    J Hum Hypertens; 2006 Jan; 20(1):45-50. PubMed ID: 16281062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
    Smink PA; Bakker SJ; Laverman GD; Berl T; Cooper ME; de Zeeuw D; Lambers Heerspink HJ
    J Hypertens; 2012 May; 30(5):1022-8. PubMed ID: 22388234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.